As Gov. Bill Lee considers final action on the FAIR Rx Act, much of the public conversation has been driven by headlines warning of pharmacy closures and reduced access. Those claims may be attention-grabbing, but they miss the real issue at the center of this legislation.
The FAIR Rx Act is not about restricting pharmacies. It is about addressing a structural conflict of interest that has quietly reshaped drug pricing and access to benefit a few giant corporations at the expense of patients and independent pharmacies.
Today, Pharmacy Benefit Managers (PBMs) act as the middlemen between insurers, drug manufacturers and pharmacies. They determine which drugs are covered, set reimbursement rates and control pharmacy networks. At the same time, many of the largest PBMs also own the pharmacies that fill those prescriptions.
(READ MORE: Letter to the editors: Cempa CEO says CVS threats of bill closing pharmacies are empty)
No other part of health care allows this level of vertical integration without scrutiny. The FAIR Rx Act simply says those roles should be separated.
